191 related articles for article (PubMed ID: 32142177)
1. Association of Tripartite Motif Containing 11 rs564309 With Tau Pathology in Progressive Supranuclear Palsy.
Valentino RR; Koga S; Heckman MG; Brushaber DE; Diehl NN; Walton RL; Dickson DW; Ross OA
Mov Disord; 2020 May; 35(5):890-894. PubMed ID: 32142177
[TBL] [Abstract][Full Text] [Related]
2. Variation at the TRIM11 locus modifies progressive supranuclear palsy phenotype.
Jabbari E; Woodside J; Tan MMX; Shoai M; Pittman A; Ferrari R; Mok KY; Zhang D; Reynolds RH; de Silva R; Grimm MJ; Respondek G; Müller U; Al-Sarraj S; Gentleman SM; Lees AJ; Warner TT; Hardy J; Revesz T; Höglinger GU; Holton JL; Ryten M; Morris HR
Ann Neurol; 2018 Oct; 84(4):485-496. PubMed ID: 30066433
[TBL] [Abstract][Full Text] [Related]
3. Association of MAPT Subhaplotypes With Risk of Progressive Supranuclear Palsy and Severity of Tau Pathology.
Heckman MG; Brennan RR; Labbé C; Soto AI; Koga S; DeTure MA; Murray ME; Petersen RC; Boeve BF; van Gerpen JA; Uitti RJ; Wszolek ZK; Rademakers R; Dickson DW; Ross OA
JAMA Neurol; 2019 Jun; 76(6):710-717. PubMed ID: 30882841
[TBL] [Abstract][Full Text] [Related]
4. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome.
Williams DR; Holton JL; Strand C; Pittman A; de Silva R; Lees AJ; Revesz T
Brain; 2007 Jun; 130(Pt 6):1566-76. PubMed ID: 17525140
[TBL] [Abstract][Full Text] [Related]
5. Protracted course progressive supranuclear palsy.
Couto B; Martinez-Valbuena I; Lee S; Alfradique-Dunham I; Perrin RJ; Perlmutter JS; Cruchaga C; Kim A; Visanji N; Sato C; Rogaeva E; Lang AE; Kovacs GG
Eur J Neurol; 2022 Aug; 29(8):2220-2231. PubMed ID: 35384155
[TBL] [Abstract][Full Text] [Related]
6. Associations of mitochondrial genomic variation with corticobasal degeneration, progressive supranuclear palsy, and neuropathological tau measures.
Valentino RR; Tamvaka N; Heckman MG; Johnson PW; Soto-Beasley AI; Walton RL; Koga S; Uitti RJ; Wszolek ZK; Dickson DW; Ross OA
Acta Neuropathol Commun; 2020 Sep; 8(1):162. PubMed ID: 32943110
[TBL] [Abstract][Full Text] [Related]
7. Latent trait modeling of tau neuropathology in progressive supranuclear palsy.
Kouri N; Murray ME; Reddy JS; Serie DJ; Soto-Beasley A; Allen M; Carrasquillo MM; Wang X; Castanedes MC; Baker MC; Rademakers R; Uitti RJ; Graff-Radford NR; Wszolek ZK; Schellenberg GD; Crook JE; Ertekin-Taner N; Ross OA; Dickson DW
Acta Neuropathol; 2021 May; 141(5):667-680. PubMed ID: 33635380
[TBL] [Abstract][Full Text] [Related]
8. Cognitive impairment in progressive supranuclear palsy is associated with tau burden.
Koga S; Parks A; Kasanuki K; Sanchez-Contreras M; Baker MC; Josephs KA; Ahlskog JE; Uitti RJ; Graff-Radford N; van Gerpen JA; Wszolek ZK; Rademakers R; Dickson DW
Mov Disord; 2017 Dec; 32(12):1772-1779. PubMed ID: 29082658
[TBL] [Abstract][Full Text] [Related]
9. Progressive supranuclear palsy: Neuropathology of patients with a short disease duration due to unexpected death.
Zhang L; Toyoshima Y; Takeshima A; Shimizu H; Tomita I; Onodera O; Takahashi H; Kakita A
Neuropathology; 2021 Jun; 41(3):174-182. PubMed ID: 33205528
[TBL] [Abstract][Full Text] [Related]
10. Rainwater Charitable Foundation criteria for the neuropathologic diagnosis of progressive supranuclear palsy.
Roemer SF; Grinberg LT; Crary JF; Seeley WW; McKee AC; Kovacs GG; Beach TG; Duyckaerts C; Ferrer IA; Gelpi E; Lee EB; Revesz T; White CL; Yoshida M; Pereira FL; Whitney K; Ghayal NB; Dickson DW
Acta Neuropathol; 2022 Oct; 144(4):603-614. PubMed ID: 35947184
[TBL] [Abstract][Full Text] [Related]
11. Divergent brain gene expression patterns associate with distinct cell-specific tau neuropathology traits in progressive supranuclear palsy.
Allen M; Wang X; Serie DJ; Strickland SL; Burgess JD; Koga S; Younkin CS; Nguyen TT; Malphrus KG; Lincoln SJ; Alamprese M; Zhu K; Chang R; Carrasquillo MM; Kouri N; Murray ME; Reddy JS; Funk C; Price ND; Golde TE; Younkin SG; Asmann YW; Crook JE; Dickson DW; Ertekin-Taner N
Acta Neuropathol; 2018 Nov; 136(5):709-727. PubMed ID: 30136084
[TBL] [Abstract][Full Text] [Related]
12. Pyramidal system involvement in progressive supranuclear palsy - a clinicopathological correlation.
Stejskalova Z; Rohan Z; Rusina R; Tesar A; Kukal J; Kovacs GG; Bartos A; Matej R
BMC Neurol; 2019 Mar; 19(1):42. PubMed ID: 30894142
[TBL] [Abstract][Full Text] [Related]
13. Accurate digital quantification of tau pathology in progressive supranuclear palsy.
Pansuwan T; Quaegebeur A; Kaalund SS; Hidari E; Briggs M; Rowe JB; Rittman T
Acta Neuropathol Commun; 2023 Nov; 11(1):178. PubMed ID: 37946288
[TBL] [Abstract][Full Text] [Related]
14. Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia.
Josephs KA; Boeve BF; Duffy JR; Smith GE; Knopman DS; Parisi JE; Petersen RC; Dickson DW
Neurocase; 2005 Aug; 11(4):283-96. PubMed ID: 16093229
[TBL] [Abstract][Full Text] [Related]
15. Genetic bases of Progressive Supranuclear Palsy: the MAPT tau disease.
Borroni B; Agosti C; Magnani E; Di Luca M; Padovani A
Curr Med Chem; 2011; 18(17):2655-60. PubMed ID: 21568901
[TBL] [Abstract][Full Text] [Related]
16. Incipient progressive supranuclear palsy is more common than expected and may comprise clinicopathological subtypes: a forensic autopsy series.
Yoshida K; Hata Y; Kinoshita K; Takashima S; Tanaka K; Nishida N
Acta Neuropathol; 2017 May; 133(5):809-823. PubMed ID: 28064358
[TBL] [Abstract][Full Text] [Related]
17. The relationship between histopathological features of progressive supranuclear palsy and disease duration.
Josephs KA; Mandrekar JN; Dickson DW
Parkinsonism Relat Disord; 2006 Mar; 12(2):109-12. PubMed ID: 16337422
[TBL] [Abstract][Full Text] [Related]
18. Neuropathological analysis of cognitive impairment in progressive supranuclear palsy.
Sakuwa M; Adachi T; Suzuki Y; Takigawa H; Hanajima R
J Neurol Sci; 2023 Aug; 451():120718. PubMed ID: 37385026
[TBL] [Abstract][Full Text] [Related]
19. An autopsy case of progressive supranuclear palsy treated with monoclonal antibody against tau.
Beck G; Yamashita R; Kido K; Ikenaka K; Chiba T; Yonenobu Y; Saito Y; Morii E; Hasegawa M; Murayama S; Mochizuki H
Neuropathology; 2023 Aug; 43(4):326-332. PubMed ID: 36593715
[TBL] [Abstract][Full Text] [Related]
20. Progressive supranuclear palsy with predominant frontal presentation exhibiting progressive nonfluent aphasia due to crossed aphasia.
Ono Y; Higashida K; Yoshikura N; Hayashi Y; Kimura A; Iwasaki Y; Yoshida M; Shimohata T
Neuropathology; 2022 Jun; 42(3):232-238. PubMed ID: 35434847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
